Bionano Genomics Inc (BNGO)

Patient Friendly Diagonsis of FSHD

Optical genome mapping is becoming a much more practical and patient friendly way to diagnose FSHD because it needs far less DNA, avoids radiation, and gives a clearer picture of the part of the genome that causes the disease. When this technology is paired with next generation sequencing to look for changes in genes like SMCHD1 or DNMT3B, doctors can evaluate both major forms of FSHD as well as other neuromuscular conditions in one streamlined approach.

With the new OGM CPT code taking effect January 1, 2026, insurance billing becomes more straightforward and predictable, making it easier for clinics to order the most advanced testing without added hassle. Revvity stands out because they already specialize in this exact combination, high resolution optical mapping plus comprehensive gene sequencing, so providers can rely on a single, experienced lab that uses the newest technology, follows the newest billing standards, and delivers clear, actionable results for patients who have been searching for answers.

Revvity Confirms OGM Outperforms Southern Blot


Why FSHD Testing + the New CPT Code Matters for BNGO

A really interesting development is starting to take shape around Bionano Genomics, and it’s something most investors haven’t connected yet. Revvity, a major global diagnostics company, has publicly highlighted that Optical Genome Mapping (OGM) can replace the old-school “Southern blot” test used to diagnose FSHD, a form of muscular dystrophy.

For decades, Southern blot has been the only way to diagnose FSHD. It’s slow, messy, requires radioactive materials, and needs a huge amount of high-quality DNA. Revvity’s own data shows that OGM does the same job faster, more accurately, and with far fewer limitations. OGM can measure the key genetic repeat involved in FSHD, detect cases where only some cells are affected (mosaicism), and identify more complex genetic patterns that Southern blot often misses. In simple terms: OGM gives doctors a clearer picture, in less time, with less hassle.

Now here’s the part that matters for investors. As of January 1, 2026, OGM officially has a Category I CPT code for constitutional genetic disorders, the category FSHD falls under. That means OGM-based FSHD testing is now reimbursable in the United States. Insurance can pay for it. Hospitals and labs can bill for it. And companies like Revvity can run these tests at scale.

This is a big deal because it turns OGM from a “cool technology” into a billable clinical service. And Revvity is already publishing data showing OGM is a better option than the current gold-standard test. When a global diagnostics company starts validating your technology publicly, and the reimbursement pathway is already in place, that’s the kind of setup that often leads to deeper partnerships, expanded testing menus, or even strategic deals.
OGM isn’t just for cancer or rare disease research anymore. It now has a clear, reimbursable role in diagnosing a real-world genetic disorder that affects families worldwide. Revvity’s endorsement shows that major players see OGM as a practical, cost-effective clinical tool. And with the new CPT code active, this opens the door for broader adoption and potentially more collaboration between Bionano and companies that want to bring OGM into their diagnostic workflows.

Bionano Genomics Relative Valuation


Relative valuation compares Bionano’s financial metrics (like price-to-sales, enterprise value-to-revenue, and price-to-book) against similar companies in the same industry.

The LSEG (London Stock Exchange Group) assigned a Relative Valuation rating of 10 to BNGO (highest rating). A rating of 10 suggests Bionano is trading at a steep discount, even though its technology, intellectual property, and clinical traction may justify a much higher valuation.

Bionano Genomics is considered extremely undervalued compared to its peers. In plain terms, the market price doesn’t reflect the company’s potential, assets, or future earnings.

According to Alpha Spread, Bionano’s a 94% undervaluation.

Bionano Genomics OGM Cash Runway


If the Illumina–Bionano collaboration evolves into the industry’s go-to standard, Illumina’s own revenues, reputation, and customer lock-in become inseparable from Bionano’s success. In that scenario, a stumble by Bionano wouldn’t just dent investor confidence in a small-cap partner, it could shake Illumina’s core sequencing business.

That alignment creates a powerful incentive for Illumina to act as a financial backstop. Whether through a strategic equity infusion, an earn-out financing arrangement or even an outright acquisition, Illumina would likely step in to shore up Bionano’s balance sheet rather than risk the global adoption of their joint platform unraveling.

By shouldering the risk, Illumina gives customers and investors confidence that this joint platform is backed by one of genomics’ strongest players, turning what once felt uncertain into a dependable engine for long-term growth for both companies.

NAYSAYERS


After years of being written off by skeptics, Bionano Genomics is about to turn the tables on the naysayers. What once was dismissed as “too niche” or “too unproven” has become the very foundation of tomorrow’s gold standard in genetic testing. Now, armed with a healthy balance sheet and a game-changing partnership with Illumina, Bionano will spotlight hidden DNA changes that nobody else can see, and make doubters eat their words.

As instruments roll into clinics and consumables are in demand, each new placement will stand as proof that thoughtful persistence beats short-sighted criticism. The naysayers will watch, with regret, as Bionano’s share price climbs alongside its reputation, and the company they once underestimated will emerge as the champion they disparaged.

ILMN $101.80 BNGO $4.02 going UP!

FDA Approval


Bionano Genomics just teamed up with Illumina, and it’s not just a tech upgrade, it’s a strategic shift that could reshape how the FDA views genome analysis. Illumina is the global leader in DNA sequencing, and now they’re integrating Bionano’s Saphyr system into their reference genome pipelines. That’s a big deal. With Illumina collaborating with Bionano Genomics, the Saphyr system is poised to be viewed through a much more serious and strategic lens.

The FDA has long recognized Illumina’s sequencing platforms as gold-standard tools for detecting small mutations. But they also know these platforms struggle with large structural changes. Saphyr fills that gap. By combining both technologies, the FDA will likely see this as a comprehensive diagnostic solution, not a competing one.

Illumina’s global reach and regulatory infrastructure give Bionano a serious boost. Illumina knows how to navigate FDA submissions, clinical trials, and reimbursement pathways. If they pursue a joint FDA submission or include Saphyr data in their own filings, it could accelerate Bionano’s path to broader approval.

If Illumina and Bionano co-develop assays that combine sequencing and optical mapping, the FDA may eventually approve them as companion diagnostics, tools used to guide treatment decisions. This would elevate Saphyr from a research tool to a clinical decision-maker.
In short, the FDA is likely to perceive Saphyr as a critical piece of a more complete genomic puzzle, especially now that Illumina is helping frame it that way. The collaboration doesn’t just boost visibility, it gives Bionano access to the regulatory muscle needed to push OGM into the clinical mainstream.

Bionano’s Share Price Popped Today


Two clear catalysts:

1. A stronger-than-expected second-quarter update—revenue climbed roughly 35 percent year-over-year, instrument placements beat guidance, and full-year revenue and instrument-installation targets were raised in an 8-K filing.

2. A new collaboration with Illumina to integrate Saphyr optical maps into their pangenome reference pipelines, giving Bionano a front-row seat in one of genomics’ hottest initiatives.

When Illumina’s software merges Bionano’s long-range maps into its network of genetic paths, labs gain a supercharged reference. Each small DNA snippet now lands exactly where it belongs, even in the trickiest stretches of the genome. The result is a clearer, more complete picture of someone’s DNA blueprint.

For researchers and clinicians, this hybrid approach means fewer errors and better detection of disease-linked rearrangements. For investors, it marks a pivotal moment: two industry leaders combining strengths to capture a larger slice of the growing market for advanced genetic analysis tools.

Active Partners Bundling Saphyr


Distributor-Embedded Workflows

Qiagen - Packages Bionano Prep Kits with its EZ1 and QiaSymphony extraction platforms.

Thermo Fisher Scientific - Offers Saphyr prep reagents alongside its Ion Torrent library kits.

Roche Diagnostics - Co-lists Saphyr instruments with its cytogenetics and microarray consumables.

MGI/BGI Genomics
Bundles optical genome mapping services with DNBSEQ sequencing.


Co-Marketing Collaborations

Illumina - Hosts joint webinars and publishes co-branded application notes showing how Saphyr orthogonally validates short-read structural calls.

PacBio - Presents hybrid assembly posters and run-through protocols at genomics conferences, linking PacBio HiFi data with Bionano OGM maps.

Oxford Nanopore Technologies - Co-sponsors workshops on merging nanopore long reads and optical maps for de novo assembly and complex-variant resolution.

PerkinElmer Genomics - Markets the EnFocus FSHD assay on Saphyr through shared sales channels, targeting neuromuscular research and diagnostic labs.


Bionano Genomics is a recognized leader in genome analysis, pioneering optical mapping with unparalleled resolution and throughput. Today, its Saphyr system sits alongside Illumina, PacBio, Thermo Fisher, and Roche in co-development initiatives and global consortiums, firmly placing Bionano among the true movers and shakers of the genomics industry.

OGM Officially Insured, Clinically Validated


Bionano Genomics’ OGM is rapidly becoming integral to genomic diagnostics.

The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a unique payment indicator to CPT 81195 in its 2025 Clinical Laboratory Fee Schedule, setting a national reimbursement rate that private payers often mirror.

Payers like Blue Cross Blue Shield and UnitedHealthcare have convened molecular pathology advisory panels in 2024 to develop internal coverage policies for OGM, citing its inclusion in CPT and CAP/AMP guidelines as the evidentiary foundation. Looking ahead, emerging CPT II codes for reporting OGM quality metrics (e.g., molecule N50, label density) are under review, which will further standardize how labs document and insurers recognize OGM performance.

NHS England’s Genomic Test Directory (April 2025) now lists OGM as an approved test under its UK-wide Genomic Medicine Service for both oncology (acute leukemias) and constitutional SV screening. Each Trust receives a defined tariff to cover OGM reagents, instrument time, and bioinformatics.

APS Medical Billing’s 2025 CPT update guide highlights CPT 81195 and assigns it to revenue codes 0300, 0309, 0310, and 0319, ensuring pathology departments know exactly how to report and track OGM claims.

BNGO - Encourage clinical labs to invest in OGM platforms and staff training.

BNGO a Blue-Chip Genomics Play


Bionano’s journey mirrors how Microsoft became a leader in artificial intelligence. Microsoft built a robust cloud platform, shared its development tools openly, and formed high-profile partnerships. Similarly, Bionano is developing a comprehensive end-to-end system, promoting open data standards, and collaborating with other technology providers.

Bionano has steadily improved its tools for studying the human genome. It began with a system called Nexus Copy Number that offered high-resolution views of DNA changes. Next came a software package that brought together different kinds of genetic information, such as large rearrangements and small mutations, into one easy-to-use program. Most recently, Bionano introduced a fully integrated platform that combines its machines, special chemicals, and analysis software into a single solution. Each step has made it faster and clearer to see the complex structure of DNA in research and clinical settings.

Many large investors still miss how far Bionano has come. They often focus on short-term sales numbers instead of the longer process of placing instruments in laboratories and building service contracts.

Bionano partnerships with top research and medical centers, new reimbursement pathways, and a growing body of published real-world studies all point to rapid, mainstream adoption. That mix of cutting-edge technology, recurring cash flow, and clear market validation makes Bionano a rare sure bet in genomics for the years ahead.

Bionano’s 10-Q and Long-Term Commitment


Bionano Genomics says it has enough cash to fund operations through at least Q1 2026, giving the company a comfortable financial runway. In fact, the filing notes up to $2 million is being set aside as a deposit to secure raw materials beyond next year’s minimum orders, an apparent move to build inventory in anticipation of stronger product demand. Finally, tucked into the back of the report you’ll find several pages detailing a major renovation of Bionano’s headquarters tied to their lease renewal, signaling management’s commitment to a long-term operational base.

Together, these items paint a picture of a company not just tightening its belt but also gearing up for the next growth phase.

Short sellers who haven’t exited may be recalculating their risk. If BNGO continues to climb ahead of its August 14 earnings report, the pressure could intensify.

OGM – Canaccord Genuity Conference


The Canaccord Genuity 45th Annual Growth Conference took place from August 12 to August 14, 2025, in Boston, Massachusetts. This event is a major venue for institutional investors to connect with high-growth companies across sectors like healthcare, life sciences, and technology, making it a prime stage for Bionano Genomics to showcase its strategic direction and innovations.

Bionano Genomics recently presented exciting updates at a major investor conference THAT HELPED BOOST ITS STOCK. The company explained how its technology, called optical genome mapping (OGM), can find big changes in DNA that other tools often miss. These changes can help doctors better understand genetic diseases.

Bionano also talked about new software that works with different types of genetic data, making it easier for labs to use their tools. They’re expanding into medical testing services too, which could bring in more money. Investors were encouraged by the company’s plan to move beyond research and into real-world healthcare, showing that Bionano might be on the path to becoming a bigger player in the genetics field.

BNGO’s New & Improved OGM


Bionano Genomics’ new VIA 7.2 software brings artificial intelligence into everyday DNA analysis. Instead of manually checking each result step by step, labs can rely on AI to spot important genetic changes in both blood disorders and inherited conditions. The program even learns from a lab’s past interpretations to get faster and more accurate over time.

VIA 7.2 also introduces a scoring system that links DNA changes to a patient’s physical traits, enabling scientists to determine which variants truly matter. Finally, it formats all results using standard genetic naming rules so that data can be easily shared and compared across different labs.

On the data-processing side, Solve 3.8.3 has grown its library of normal genetic variations by 18 percent. This bigger control database means the software is better at catching true positives, avoiding false alarms, and seeing smaller changes in the DNA. In practical terms, researchers will spend less time double-checking results and more time focusing on discoveries.

The Stratys Compute server has received a powerful boost from upgraded GPU chips. These graphics processors let labs analyze up to twice as many cancer samples each week compared with older versions. They’ve also unlocked analysis pipelines that used to run only on slower CPU servers, so labs get faster results without changing their existing workflows.

Together, these upgrades make OGM faster, smarter, and more scalable, key improvements for any lab thinking about adding this technology.

Bionano officially announced the new Stratys Compute upgrades on August 5, 2025. These enhancements are currently being deployed to 20 early-access sites, with a full commercial launch slated for the fourth quarter of 2025.

August 7, 2025 – OGM in Childhood Leukemia


Bionano Genomics Update: OGM Shows Promise in Rare Childhood Leukemia Cases

Here is exciting news from a peer-reviewed study led by researchers in France. The study focused on a rare and aggressive form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL), specifically in infants and toddlers under 3 years old, a group that’s notoriously hard to analyze due to the rarity and complexity of their cancers.

Using Bionano’s Optical Genome Mapping (OGM) technology, the researchers were able to detect important genetic changes, called structural variants, that traditional methods missed. These genetic markers help identify what’s driving the cancer and how severe it might be.

In a national review of 27 cases, OGM was part of a combined testing approach alongside targeted DNA and RNA sequencing. This multi-layered strategy uncovered distinct subgroups of patients with different risk levels, which could be crucial for tailoring treatment.

Bottom line: The study supports using OGM as a powerful add-on to standard genetic tests. It helps doctors better understand rare childhood cancers and could improve how patients are classified and treated.

Accelerating Bionano’s OGM Adoption


Hands-on training, combined with emerging guidelines and policy support, has rapidly lowered barriers for OGM implementation in European hospital and research labs.
Early 2025 saw EU health policy reforms introduce reimbursement pathways for advanced genomic diagnostics, encouraging hospital labs to adopt OGM for cancer and rare disease testing.

Strategic collaborations begun in Q1 2025 between OGM providers and leading academic centers, such as the Max Planck Institute, have generated clinical validation data in lymphoma and leukemia applications, fueling confidence among clinical lab directors.

More than a dozen European clinical laboratories, spanning Germany, France, Italy, and the UK, have already initiated pilot OGM workflows following workshop attendance and are engaging Bionano for on-site VIA™ integration support.

Requests for advanced masterclasses on custom pipeline development and cloud-based VIA™ deployment surged by over 60% in the month after the workshops, signaling strong demand for deeper technical training and support.

These combined efforts are catalyzing the integration of Bionano Genomics’ OGM into routine diagnostics, with full clinical adoption expected to accelerate throughout 2025 and beyond.

Someone asked about Stratys. Many published studies and clinical validations were conducted using Saphyr. Stratys is newer, and while it's more powerful, it’s still being rolled out and adopted. Think of Saphyr as the trailblazer, and Stratys as the evolution, same core technology, but optimized for speed, scale, and flexibility.

Hematologic Malignancies - OGM


Bionano Genomics’ Saphyr system excels at detecting structural variants and copy-number changes that can be missed by traditional karyotyping or FISH. Key blood cancers where Saphyr adds value include:
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphoblastic Leukemia (ALL)
Non-Hodgkin and Hodgkin Lymphomas

Saphyr is widely regarded as the top optical genome mapping platform for hematologic malignancies, thanks to its resolution, throughput, and comprehensive Structual Variants coverage.

SVs affect more of the genome on average than single-nucleotide variants. A typical human carries around 8.9 Mbp of SVs compared to 3.6 Mbp of SNVs, and these larger changes can disrupt genes, alter dosage, or generate fusion genes underlying many genetic disorders and cancers.

SNVs - They represent the most frequent type of genetic variation in humans and can act as drivers of diversity, disease susceptibility, or therapeutic response.

OGM – Overcoming FDA’s stranglehold

Optical Genome Mapping (OGM) from Bionano Genomics has been adopted by leading research facilities across Europe, Asia, and Australia, enabling precise detection of complex structural variants at a scale and resolution previously unimaginable.

In clinical settings, hospitals and specialty clinics such as the Wellcome Sanger Institute, Children’s Hospital of Philadelphia, and University Medical Center Utrecht have leveraged OGM to refine diagnoses in hematological and rare genetic disorders, accelerating time to treatment and improving patient outcomes.

National health authorities in the United Kingdom, Japan, Switzerland, and Canada have issued administrative approvals for OGM platforms, integrating them into regulatory frameworks for diagnostics and patient care.

Despite these global successes, the U.S. Food and Drug Administration has imposed protracted review timelines on OGM systems, influenced by political pressures and entrenched commercial interests that prioritize incumbent technologies over patient-centered innovation.

Bionano Genomics - Dynasty Building 101


BIONANO GENOMICS has orchestrated a powerful alliance across technology, automation, software, and clinical diagnostics to bring Optical Genome Mapping (OGM) to market with precision and scale. MICROSOFT provides the cloud infrastructure that powers high-speed genomic analysis, while BioDISCOVERY’s software suite integrates OGM with other genomic platforms for seamless interpretation. DIAGENS enhances diagnostic accuracy through AI-driven analysis, especially in reproductive health, and LINEAGEN delivers clinical testing directly to patients, validating OGM’s utility in neurodevelopmental disorders. REVVITY supports reagent consistency and workflow automation, ensuring global scalability. HAMILTON and TECAN round out the ecosystem by automating sample preparation and lab workflows, making OGM plug-and-play for clinical labs. Together, these partners form a synchronized pipeline, from DNA extraction to clinical insight, that positions OGM as a disruptive yet enduring force in precision medicine.

Microsoft (MSFT) $503.32 a share
Revvity (RVTY) $101.50 a share
Bionano Genomics (BNGO) $3.40 a share

“If you want to soar like an eagle, don’t hang out with turkeys.”

Microsoft’s Understated Role in OGM


When people talk about Bionano Genomics, they usually focus on things like FDA approval, new diagnostic tests, or how it’s changing the way genetic diseases are diagnosed. But behind the scenes, one of the biggest names in tech is quietly making it all run smoother… Microsoft.

Back in 2021, Bionano teamed up with Microsoft to help tackle a big challenge, how to process massive amounts of genetic data quickly and efficiently. Instead of relying solely on their own computing power, Bionano tapped into Microsoft’s cloud platform. That move cut their analysis time by nearly a third and saved them more than half of their compute costs. For researchers and doctors, that means faster answers and lower costs, which can translate to better care for patients.

This collaboration hasn’t been widely talked about, but it’s making a real difference. Microsoft’s cloud tech helps Bionano scale its reach, whether it’s analyzing complex genetic conditions or preparing for broader clinical use. While other headlines focus on market speculation and clinical milestones, this partnership is quietly helping Bionano become a more efficient and reliable player in the world of medical diagnostics.

Microsoft may not be in the spotlight here, but their tools are powering real change behind the scenes.

Bionano Genomics’ acquires, affiliations & partnerships: Microsoft, BioDiscovery, Diagens, Lineagen, Revvity, Hamilton, and Tecan. I think I have all of them?

BNGO $3.40

OGM & NGS – The Future of Clinical Genomics


The future of genomic diagnostics is here, and it’s all about Optical Genome Mapping (OGM) and Next-Generation Sequencing (NGS). Together, they’re replacing outdated methods like karyotyping, microarrays, and FISH with a faster, more accurate workflow.

OGM reveals the structural blueprint of the genome, catching large variants that sequencing misses and NGS delivers the fine details, spotting single-base changes with precision.

Integrated platforms now combine both in one streamlined view, boosting diagnostic yield, cutting turnaround time, and simplifying lab operations.

This isn’t just evolution, it’s a complete shift in how labs deliver answers. Investors should pay attention: OGM and NGS are becoming the new foundation of clinical genomics, leaving legacy methods behind. The companies enabling this transition are shaping the future of precision medicine.

INVESTORS SHOULD PAY ATTENTION! “BNGO”

BNGO - From Lab Bench to Wall Street Buzz


Bionano’s true value lies beneath the surface. It’s not just a device maker — it’s the foundation of a worldwide genomic infrastructure. As Wall Street catches on, early believers stand to benefit most.

Diagens (China): A pioneering Bionano Genomics partner bringing AI-driven chromosome analysis into reproductive health across Chinese hospitals. It’s already approved for clinical use in China, a major regulatory milestone.

BioDiscovery (USA): Acquired to strengthen Bionano’s software strategy. Its clinical platform merges optical genome mapping with sequencing data, giving geneticists unmatched insight into structural variants.

Lineagen (USA): Now operating as Bionano Laboratories, it provides clinically certified diagnostics for children with neurodevelopmental disorders, a vital step toward insurance reimbursement and mainstream medical adoption.

Revvity (Global): A strategic collaboration expands Bionano’s software into newborn sequencing workflows worldwide, embedding the company into clinical genomics from day one.

Hamilton (Switzerland): Co-developed the Long String VANTAGE workstation with Bionano — the first fully automated system for extracting ultra-high molecular weight DNA, a prerequisite for optical genome mapping. Hamilton’s global reputation in precision liquid handling makes this partnership a vote of confidence in Bionano’s tech.

Tecan (Switzerland): OEM partner supporting automation of Bionano’s workflows, including DNA extraction and sample prep. Tecan’s platforms are widely used in genomics labs worldwide, and its collaboration with Bionano positions OGM for plug-and-play integration into existing infrastructure.

OGM - Myth Busting 101


BIONANO GENOMICS (BNGO)

MYTH #1: “OGM is just for research.”
FACT: OGM is rapidly entering clinical workflows worldwide.
A new international expert panel just recommended OGM as a first-tier test for blood cancers.
OGM is now used in preimplantation genetic testing, helping families avoid passing on complex chromosomal disorders.
Johns Hopkins found OGM outperformed karyotyping and FISH in solid tumor diagnostics, and identified actionable variants in 98% of cases when paired with NGS.

MYTH #2: “Saphyr is outdated.”
FACT: Meet Stratys - the next-gen OGM system.
4x the throughput of Saphyr
12-sample random access chips (no batching!)
On-site AI-powered analysis with Stratys Compute
Already adopted in the U.S., Europe, Canada, and the Middle East

MYTH #3: “No path to reimbursement.”
FACT: Bionano now has two Category I CPT codes from the AMA.
One for hematologic malignancies
One for constitutional genetic disorders
These are permanent, billable codes, a major step toward routine clinical adoption

MYTH #4: “No global traction.”
FACT: OGM is going worldwide.
Featured at ESHG 2025 in Milan, Italy
Used in China for successful In Vitro Fertilization outcomes
Adopted by leading labs in Saudi Arabia, Germany, and Canada
CLIA labs in the U.S. are already offering OGM-based tests

OGM is not a fringe tool. It’s a scalable, clinically validated platform with global momentum, growing reimbursement, and next-gen tech in Stratys. The future of genomics isn’t coming, it’s already here.

OGM - Standard-of-Care in Blood Cancers


The International Consortium for Optical Genome Mapping has ENDORSED Optical Genome Mapping as a new standard-of-care tool for diagnosing blood cancers. Published in the American Journal of Hematology, the expert consensus supports REPLACING OUTDATED METHODS like karyotyping and FISH with this modern, high-resolution approach.

The endorsement highlights Optical Genome Mapping's ability to detect hidden genomic variants, improve risk assessment, and support personalized treatment. Conditions like leukemia, myelodysplastic syndromes, and multiple myeloma are among those expected to benefit from earlier and more accurate diagnosis.

Bionano Genomics OGM - Worldwide


EUROPE: Conformité Européenne marking confirms that a diagnostic device meets the European Union’s standards. Bionano has submitted its genome-mapping system and accompanying test kits for this marking, enabling hospitals and independent laboratories across Europe to use the technology for patient diagnosis rather than research alone. Receipt of this approval would allow routine testing of structural genetic variants in clinical settings from SCANDINAVIA to southern FRANCE, accelerating adoption in hereditary disease screening and oncology.

JAPAN: Bionano’s submission dossier detailing analytical performance, clinical validation and risk analysis is under review, paving the way for official clearance.

CANADA: In Canada, Health Canada approval involves a detailed review of device safety and clinical utility. Bionano has initiated the application process to secure this license.

AUSTRALIA: In Australia, the Therapeutic Goods Administration oversees diagnostic device listings. Bionano’s system is being evaluated under the higher-risk category for in vitro diagnostic use.

CHINA: Engagement with China’s National Medical Products Administration commenced with a technical consultation, defining the performance metrics required for clinical claims. Approval here would tap one of the world’s largest genomic-testing markets, allowing regional laboratories to offer high-resolution structural-variant testing for oncology and rare diseases.

Why These Approvals Matter

Each new country license reduces regulatory risk, making Bionano’s technology a globally recognized standard for clinical genome mapping. Widespread approval underpins partnerships with local distributors, laboratory networks and regional centers of excellence, driving recurring revenue through consumable kit sales.

Bionano Genomics’ OGM – FDA status


Bionano is describing a two-step regulatory approach:

1. Secure formal approval for today’s laboratory-developed tests
They have tests that are designed, validated and run entirely within certified clinical laboratories under federal laboratory quality rules. Bionano’s first priority is to submit those existing tests to the federal food and drug agency for official clearance as diagnostic products.

2. Move on to the next-generation instrument once those tests are approved
After their current tests gain formal clearance, Bionano will turn its attention to filing for approval of the newer, higher-capacity genome-mapping machine. By proving the agency’s requirements on their established workflows first, they build experience, documentation and credibility—making it smoother to secure approval for their next-generation platform.

BNGO - Sovereign of Structural Variants


The Q1 2025 results for Bionano Genomics (BNGO) were a masterclass in execution, with revenue soaring 40% year-over-year to $24.3 million. But beyond the numbers lies a deeper truth: Bionano is now a category-defining force in precision genomics, leveraging its Saphyr optical genome mapping (OGM) platform to carve out a niche where rivals like Illumina (ILMN) cannot compete. This is a company at an inflection point, with accelerating adoption in oncology and rare disease research, a widening competitive moat, and a roadmap to capitalize on a $10 billion addressable market. For investors, the question isn’t whether to buy—it’s when.

Collaboration with automation leaders (Tecan, Hamilton), informatics partners (BioDiscovery), and specialty labs (Lineagen) ensures seamless workflows and broadens adoption. REVVITY (formerly Avantor/PerkinElmer Life Sciences) collaborates with Bionano to ensure global supply chain and reagent consistency. Partnership with DIAGENS exemplifies how AI can unlock OGM’s full potential by automating interpretation, reducing reliance on expert cytogeneticists and accelerating turnaround.

Collectively, these collaborations enable a frictionless OGM workflow, from DNA extraction through data interpretation, paving the way for broader clinical deployment in oncology, reproductive health and constitutional genetics.

Bionano Genomics OGM – Hope abounds

Bionano’s disciplined regulatory pathway execution significantly de-risks the timeline to market and enhances visibility for institutional investors. By aligning early with FDA expectations and building a rigorous evidence base, the company is poised to secure moderate-risk De Novo clearance within 6–12 months of submission.

With every layer of regulatory engagement thoughtfully addressed, Bionano is executing on a clear path toward mainstream clinical adoption, offering investors a uniquely positioned genomics innovator at the cusp of a new era in precision diagnostics.

A voluminous external evidence portfolio reframes OGM from “highly novel” to “clinically validated,” reducing perceived risk.

Peer-reviewed and international IVD data feed directly into analytical/clinical validation sections, satisfying FDA performance-threshold requirements.

Consistent global use cases inform intended-use claims and specimen requirements, pre-empting common agency queries.

These worldwide endorsements dramatically de-risk Bionano’s De Novo petition by shifting the narrative from “emerging technology” to “clinically proven standard,” positioning Saphyr for an expedited review, smoother reimbursement discussions and a clear path to global commercialization.

Bionano Genomics (BNGO) OGM Overall Takeaway


Clinicians and diagnostic laboratories worldwide are incorporating OGM into their workflows. Early adopters report improved detection rates for cryptic rearrangements and balanced translocations, leading to faster, more accurate diagnoses. The technique’s versatility (from rare pediatric diseases to adult-onset malignancies) has catalyzed pilot programs across Europe, North America, and Asia Pacific.

Global sentiment on OGM is distinctly positive. Researchers laud its technical advances, clinicians see clear patient-care benefits, and investors recognize its market potential. Together, these endorsements position OGM to become a standard in genome structural analysis.

BNGO receives Kudos from ACMG & CAP


ACMG: American College of Medical Genetics and Genomics
CAP: College of American Pathologists

ACMG calls out OGM as an “emerging technology” that can “comprehensively detect genome-wide structural variants at kilobase resolution,” supplementing karyotype, FISH and sequencing for solid-tumor workups.

CAP & ACMG Cytogenetics Committee planned action is “to define and monitor state-of-the-art and emerging technology in both conventional and molecular cytogenetics and cytogenomics,” naming methods like OGM as part of that goal.

CAP published a standalone OGM guideline, but it co-sponsors ACMG’s standards and incorporates their recommendations into proficiency testing and accreditation checklists.

GREAT NEWS!!! Bionano Genomics’ OGM




Q. What are the reviews of Bionano Genomics’ participation in the European Society of Human Genetics (ESHG) conference held in Milan, Italy, from May 24-27, 2025?

AI’s Answer: “In short, the shop talk is that OGM has leaped from “exciting new tech” to “must-have cytogenetics backbone,” and everyone at ESHG left convinced it’s poised to rewrite diagnostic workflows worldwide.”

OGM – Hamilton & Tecan (WHO?)


In June 2022, Hamilton Bonaduz AG and Bionano Genomics jointly unveiled the Long String VANTAGE workstation—the first fully walk-away automation solution for isolating ultra-high-molecular-weight (UHMW) DNA specifically for OGM.
This turnkey platform marries Hamilton’s precision liquid-handling with Bionano’s Prep SP chemistry to streamline the critical first step in optical mapping.

This OEM partnership locks in a critical sample-prep piece for Bionano’s OGM pipelines while giving Hamilton a unique genomics-automation offering—so it’s a true win-win on workflow integration.

As Bionano rolls out Stratys Plus consumables and targets higher-throughput customers, they’ll want turnkey “OGM-ready” modules. Tecan’s already laid the groundwork; during H2 2024 you may see a true plug-and-play demo or even an OEM-branded kit.

Letter Sent to FDA


druginfo@fda.hhs.gov

To the U.S. Food and Drug Administration,

I am writing to express deep concern over the continued lack of clinical approval for Optical Genome Mapping (OGM) technologies, such as those developed by Bionano Genomics. These tools are already in use at leading institutions like Johns Hopkins and MD Anderson, where they are helping researchers uncover structural variants that traditional methods often miss.

Patients with life-threatening diseases—especially rare cancers and genetic disorders—deserve access to the most advanced diagnostic technologies available. OGM has demonstrated its value in real-world research and translational settings. The delay in regulatory approval is not just a bureaucratic issue; it is a barrier to care.

I urge the FDA to prioritize a modernized, responsive framework that reflects the pace of genomic innovation. Patients cannot afford to wait for outdated processes to catch up with life-saving science.

The FDA replied: Thank you for contacting the Division of Drug Information (DDI), your email is very important to us. Due to the HHS restructuring, effective April 1, 2025, our response time may vary. Thank you for your patience.

Several prominent American institutions and organizations are actively supporting and showcasing the power of Optical Genome Mapping (OGM) in genomic diagnostics:

MD ANDERSON CANCER CENTER has integrated Bionano’s OGM into its Advanced Technology Genomics Core.

COLUMBIA UNIVERSITY MEDICAL CENTER is a key academic voice.

GREENWOOD GENETIC CENTER led by Dr. Roger Stevenson, has used OGM and, emphasizes its diagnostic clarity.

The COLLEGE of AMERICAN PATHOLOGISTS has also spotlighted OGM’s potential, noting its superior resolution and ability to detect structural variants that traditional methods often miss. They describe it as a transformative tool bridging discovery and diagnostics.

JOHNS HOPKINS DEP’T of PATHOLOGY presented a study on multiple myeloma showing that OGM revealed a more comprehensive genome-wide profile than traditional methods like FISH and karyotyping.

Is the FDA paying attention or playing politics?

BNGO’s OGM & FDA’s Inertia

When a technology like Bionano’s Optical Genome Mapping (OGM) is embraced globally, with mounting clinical evidence and real-world impact, it’s fair to ask: why hasn’t the FDA moved faster?

There’s no official statement from the FDA denying OGM or citing political reasons. But some observers and stakeholders have speculated that bureaucratic inertia, entrenched diagnostic paradigms, or even geopolitical dynamics may be slowing the process. For example, while China’s regulatory body has approved OGM for clinical use in reproductive health, the U.S. has yet to follow suit—even as researchers from France, Germany, Spain, and Brazil continue to validate its clinical utility.

This isn’t just about red tape—it’s about patients waiting for answers. And when a tool like OGM can detect structural variants that traditional methods miss, the stakes are deeply personal.

For patients with rare diseases, unresolved neurodevelopmental delays, or undiagnosed hematologic cancers, this isn’t just about better science—it’s about getting a real answer after years in limbo.

Bionano Genomics' Edge


Bionano Genomics’ integrated ecosystem gives it a significant edge in the complex landscape of genomics. By combining the advanced optical genome mapping (OGM) technology with BioDiscovery’s sophisticated analytics, Lineagen’s clinical diagnostic capabilities, Revvity’s strategic market integration, and Diagens’ specialized innovations, the company creates a robust, end-to-end approach that many competitors simply don’t match.

The AMA says YES to OGM. The FDA says NO.


It certainly seems that way. Optical Genome Mapping (OGM) has demonstrated undeniable clinical value, yet regulatory approval remains elusive. Despite major institutions like Johns Hopkins and MD Anderson validating its effectiveness, the FDA’s prolonged silence raises concerns about whether patient-centered innovation is being overshadowed by bureaucratic and financial influences.

Big money’s got its boot on OGM’s neck!

Dr. Makary Emphasizes AI in the FDA
Dr. Makary Emphasizes AI in the FDA


With technologies like Optical Genome Mapping (OGM) proving their scientific and clinical merit, AI-driven evaluation systems could ensure objective assessments that rely strictly on current research and proven successes—not on outdated standards or industry politics. The more AI integrates into medical decision-making, the harder it will be for human bias to override the facts.

With the FDA’s AI actively synthesizing global research, backed by Microsoft’s extensive medical database, and leading institutions like Johns Hopkins and MD Anderson Cancer Center championing Optical Genome Mapping (OGM), the momentum for rapid adoption is undeniable.

KJ Baby - Big Opportunity for Bionano Genomics


With the world watching KJ’s treatment, Bionano could step in and showcase how OGM enhances gene therapy safety. By offering OGM for structural validation and monitoring, they could help establish best practices for genomic stability checks after gene editing—a crucial aspect of future treatments.

OGM could become a standard tool in gene therapy, ensuring that treatments like KJ’s remain safe and effective for years to come.

AMA Gives OGM New Category I CPT Code


Before – Doctors mainly used OGM for cancer testing. It helped find genetic mutations in diseases like leukemia.

Now – OGM can also be used to study genetic conditions people are born with, like intellectual disabilities or inherited diseases.

Insurance helps cover it – Because it's officially approved, insurance companies are more likely to pay for OGM testing, so patients don’t have to cover all the costs.

How this affects cases like Baby KJ at CHOP – Baby KJ got a gene-editing treatment for a rare disease. Since OGM is more widely accepted, doctors can check for genetic changes before and after treatment to make sure everything is working correctly.

This means more patients can get tested, more hospitals can use OGM, and it’ll help doctors make better diagnoses for both cancer and genetic disorders.

1st customized CRISPR gene-editing treatment


World's First! In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children’s Hospital of Philadelphia (CHOP) and Penn Medicine.

Potential Impact on Bionano’s Saphyr System

Complementary Technologies – CRISPR focuses on gene editing, while optical genome mapping (OGM) with Saphyr excels at detecting structural variants (SVs). The two technologies could work together to improve genetic diagnostics and personalized treatments
.
Advancing Rare Disease Research – CHOP’s CRISPR breakthrough demonstrates the power of targeted genetic corrections, which could lead to more demand for high-resolution genome mapping. an area where Saphyr is highly effective.

Regulatory & Clinical Adoption – The success of CRISPR-based therapies could accelerate FDA approvals for advanced genomic tools, potentially benefiting OGM adoption in clinical settings.

Competitive Landscape – As CRISPR gains traction, institutions may look for complementary technologies like OGM to validate genetic modifications and ensure comprehensive genomic analysis.

OGM & FDA: The Saga Continues


The FDA’s shift toward AI-based computational models for drug testing could pave the way for optical genome mapping (OGM) to gain regulatory approval. The agency is phasing out animal testing in favor of human-relevant methods, including AI-driven toxicity models, organ-on-a-chip systems, and computational simulations.

While the FDA has not yet issued specific guidance on OGM, its focus on advanced genomic tools suggests that technologies like OGM could be fast-tracked for validation in clinical diagnostics and drug development.

If FDA approves OGM – BNGO shares will Soar!

The MD Anderson Cancer Center study on Optical Genome Mapping (OGM) is helping pave the way for new regulatory approval pathways by demonstrating OGM’s clinical utility in hematologic malignancies.

Given OGM’s ability to detect structural variants missed by traditional cytogenetics, it could qualify for expedited FDA review under the Breakthrough Devices Program.

If OGM continues to show superior sensitivity and clinical relevance, it could be incorporated into National Comprehensive Cancer Network (NCCN) guidelines, influencing oncology best practices.

As OGM gains traction, insurers may begin coverage discussions, making it more accessible for clinical applications.
Countries like China and the EU are evaluating OGM for clinical use, which could accelerate global adoption.

These pathways could fast-track OGM’s integration into clinical workflows, making it a standard-of-care tool for cancer diagnostics.

Is BNGO a sophisticated Scam?

Independent studies from prestigious institutions like Johns Hopkins Hospital and MD Anderson Cancer Center have validated Optical Genome Mapping (OGM) as an advanced tool for detecting structural variants missed by traditional sequencing methods.

Major hospitals and research centers—including Johns Hopkins, MD Anderson, Greenwood Genetic Center, and Radboud University Medical Center—are actively integrating OGM into their clinical and research workflows.

Peer-reviewed research has demonstrated OGM’s effectiveness in hematological malignancies, rare diseases, and oncology applications, proving its real-world utility.

Bionano Genomics’ OGM is a Sophisticated technology.

BNGO.............................https://stockcharts.com/h-sc/ui?s=BNGO&p=W&b=5&g=0&id=p86431144783

Anderson Cancer Center’s Impact on OGM


MD Anderson Cancer Center’s endorsement of Optical Genome Mapping (OGM) carries significant weight in the medical and genomics communities. As one of the leading cancer research institutions, its validation of OGM’s utility in hematological malignancies and structural variant detection could accelerate adoption across clinical and research settings.

Additionally, MD Anderson’s involvement in scientific presentations and case studies showcasing OGM’s ability to detect pathogenic structural variants strengthens its credibility. This could lead to increased funding, broader institutional acceptance, and potential inclusion in medical guidelines.

BNGO - Why “RISK” OGM

American companies that share their intellectual property (IP) with China often face significant risks, including forced technology transfers, IP theft, and regulatory manipulation. The Chinese government has a history of leveraging its legal and regulatory system to coerce technology transfer or appropriate foreign innovations for domestic use. High-profile cases, such as DuPont, Micron, and Tesla, illustrate how Chinese entities have allegedly exploited partnerships, poached talent, and engaged in outright theft to gain access to proprietary technologies. Additionally, China’s Cybersecurity Law grants its government broad access to data stored within its borders, raising concerns about espionage and unauthorized IP extraction.

BUT, Bionano Genomics, for reasons unkown, feels it is an exception to the Chinese threat.

Enter the partnership with Diagens, a Chinese company

Do we really need Bionano Genomics' OGM?

Optical Genome Mapping (OGM) offers advantages over traditional methods like FISH, PCR, and CMA by detecting large structural variations with higher resolution. While these older techniques can identify specific genetic mutations, they often require multiple tests to get a full picture, whereas OGM consolidates genomic analysis into one streamlined workflow, improving accuracy in cancer and rare disease research.

Although transitioning to OGM involves an initial investment, it can save time and costs by reducing the need for multiple separate tests. Many leading institutions are integrating OGM with sequencing technologies to ensure both sequence-level and structural insights, making it a future-ready approach for comprehensive genomic analysis.

Bionano Genomics ain’t going out-of-business.

Several financially sound research institutions and organizations are actively combining Next-Generation Sequencing (NGS) with Optical Genome Mapping (OGM).

Researchers at Johns Hopkins have published studies demonstrating how OGM outperforms traditional cytogenetic assays and complements NGS in cancer research.

University of California, San Francisco researchers have combined OGM with NGS to improve detection of clinically relevant genetic variants, particularly in genetic disease research.

MD Anderson Cancer Center has explored the integration of OGM and NGS for structural variant profiling in myelodysplastic syndrome (MDS) research.

Children’s Hospital Los Angeles researchers here have used OGM and RNA sequencing to improve molecular subtyping in pediatric leukemia cases.

These institutions are well-established and financially robust.